[CAS NO. 1001409-50-2] MP7
PRODUCTS SPECIFICATIONS [1001409-50-2]
DESCRIPTION [1001409-50-2]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 516.50 |
| Molecular Formula | C28H22F2N4O4 |
| SMILES | O=C(C1=CC=CN(CC2=CC=C(F)C(F)=C2)C1=O)N[C@H](C3=CC=CC=C3)COC4=CC=C(N5)C(NC5=O)=C4 |
Summary
MP7 (PDK1 inhibitor) is a phosphoinositide-dependent kinase-1 ( PDK1 ) inhibitor.
IC50 & Target
PDK1 [1]
In Vitro
Cell counting of U87MG-derived glioma stem cells (GSCs) confirms that Alisertib and, to a minor extent, MP7 (PDK1 inhibitor) are able to decrease the number of viable cells. When combined together, GSC viability is further reduced with respect to single-treated cells. As observed in U87MG cells, when used at the highest concentrations (i.e., 1.5 μM Alisertib and 2.5 μM MP7), a significant enhancement in the number of dead cells is evidenced. Following 72 h treatment, MP7 alone does not show a significant inhibition of glioblastoma multiforme (GBM) proliferation. MP7 has been shown to have only minimal effects on monolayer cell growth in several cancer cell lines, with IC 50 values in the micromolar range [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 100 mg/mL ( 193.61 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.9361 mL | 9.6805 mL | 19.3611 mL |
| 5 mM | 0.3872 mL | 1.9361 mL | 3.8722 mL |
| 10 mM | 0.1936 mL | 0.9681 mL | 1.9361 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.75 mg/mL (5.32 mM); Clear solution